Background: Pupillometry is used for the detection of autonomic dysfunction related to numerous diseases and drug administration. Genetic variants in cytochrome P450 (CYP2D6, CYP3A4), dopamine receptor (DRD2, DRD3), serotonin receptor (HTR2A, HTR2C) and ATP-binding cassette subfamily B (ABCB1) genes were previously associated with aripiprazole response. Aims: Our aim was to evaluate if aripiprazole affects pupil contraction and its relationship with pharmacokinetics and pharmacogenetics. Methods: Thirty-two healthy volunteers receiving a 10 mg single oral dose of aripiprazole were genotyped for 15 polymorphisms in ABCB1, CYP2D6, DRD2, DRD3, HTR2A and HTR2C genes by reverse transcription polymerase chain reaction. Aripiprazole and dehydro-aripiprazole plasma concentrations were measured by high-performance liquid chromatography tandem mass spectrometry. Pupil examination was performed by automated pupillometry. Results: Aripiprazole caused pupil constriction and reached the peak value at C max . HTR2A rs6313 T allele carriers and HTR2C rs3813929 C/T subjects showed higher maximum constriction velocity and maximum pupil diameter. Besides, Gly/Gly homozygotes for DRD3 rs6280 showed significantly lower maximum constriction velocity values. A/G heterozygotes for DRD2 rs6277 showed higher total time taken by the pupil to recover 75% of the initial resting size values. CYP2D6 intermediate metabolisers showed higher area under the curve, C max and T 1/2 than extensive metabolisers. ABCB1 G2677T/A A/A homozygotes had greater T 1/2 in comparison with C/C homozygotes. ABCB1 C3435T T allele carriers and C1236T C/T subjects showed greater area under the curve than C/C homozygotes. Conclusions: Aripiprazole affects pupil contraction, which could be a secondary effect through dopamine and serotonin receptors. Pupillometry could be a useful tool to assess autonomic nervous system activity during antipsychotic treatment.
Introduction
Schizophrenia is a chronic and relapsing disorder with generally incomplete remissions, variable degrees of functional impairment and social disability (Alves et al., 2005) . Aripiprazole (ARI) is a quinolinone derivative which belongs to the atypical (second generation) antipsychotics commonly prescribed for patients with acute relapse of schizophrenia or schizoaffective disorders. Doses from 15-30 mg once a day are effective and well tolerated by patients (McGavin and Goa, 2002) . This drug has partial agonist activity at dopamine D2, D3 and serotonin (5-HT)1A receptors, and acts also as a 5-HT2A and 5-HT7 receptor antagonist (de Bartolomeis et al., 2015; Lawler et al., 1999; Stip and Tourjman, 2010) . The main active metabolite, dehydro-aripiprazole (DARI), amounts to 40% of the parent compound in plasma, has high affinity towards dopamine D2 receptors and is an antagonist at 5-HT2A receptors. Therefore, DARI has some pharmacological activity similar to ARI (Kirschbaum et al., 2008; Taylor, 2003; Wood et al., 2006) .
The metabolism and elimination of ARI is mainly mediated through two cytochrome P450 enzymes, CYP2D6 and CYP3A4. CYP3A4 is responsible for N-dealkylation and both CYP2D6 and CYP3A4 mediate dehydrogenation and hydroxylation of the drug leading to the main metabolite DARI (Kirschbaum et al., 2008; Urichuk et al., 2008) . The mean elimination half-life is about 75 h for ARI, however, for individuals who do not have sufficient CYP2D6 activity (poor metabolisers; PMs), this can be about 146 h (Dean, 2012a) . Approximately 8% of Caucasians cannot metabolise CYP2D6 substrates and are classified as PMs Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects (Gaedigk et al., 2017) . Patients carrying three or more active CYP2D6 alleles (up to 7% in Caucasians) , are called CYP2D6 ultra-rapid metabolisers (UMs) (de Leon et al., 2006; Dean, 2012b) .
Genetic variants of different genes related to the ARI response were analysed in previous studies. A1/A1 genotype for DRD2 Taq1A genetic variant (rs1800497) was reported as a predictor of positive symptom improvement on ARI treatment in patients with schizophrenia (Kwon et al., 2008) . In case of -141C Ins/Del (rs1799732) polymorphism, Del allele carriers were associated with lower antipsychotic drug response, compared to Ins/Ins genotype (Zhang et al., 2010) . Another study showed that Gly/ Gly genotype was more common among schizophrenia patients than Ser/Ser genotype for DRD3 Ser9Gly (rs6280) polymorphism in comparison with healthy controls, therefore, Gly/Gly can be considered as a risk factor for the disease (Loch et al., 2015) . Moreover, between paediatric patients under antipsychotic treatment the ATP Binding Cassette Subfamily B Member 1 (ABCB1, coding for P-glycoprotein) T allele carriers for G2677T/A and C3435T polymorphisms had significantly lower plasma concentration/dose ratio for ARI related to patients with other ABCB1 genotypes (Rafaniello et al., 2017) . Furthermore, it was found that subjects carrying G/G genotype for HTR2A A-1438G (rs6311) and C/C genotype for T102C (rs6313) polymorphisms have a poorer ARI response, especially for negative symptoms (Chen et al., 2009) . Additionally, carrying the C allele of HTR2C -759C/T (rs6318) polymorphism was confirmed to influence weight gain following antipsychotic treatment (Ma et al., 2014) .
The iris size, and therefore the pupillary diameter, is controlled by two muscles, the sphincter pupillae and the dilator pupillae, which are mainly under the regulation of the parasympathetic nervous system and the sympathetic nervous system, respectively. Contraction of the sphincter, accompanied by the relaxation of the dilator, produces pupil constriction (miosis), while contraction of the dilator, accompanied by the relaxation of the sphincter, produces pupil dilation (mydriasis) (McDougal and Gamlin, 2014) .
Since pupillography was developed in 1958 (Lowenstein and Loewenfeld, 1958) , it is used for the detection of autonomic dysfunction associated with numerous diseases, such as diabetes (Piha and Halonen, 1994) , heart failure (Keivanidou et al., 2010 ), Parkinson's disease (Jain et al., 2011 ), Alzheimer's disease (Fotiou et al., 2000) and hypertension (Koike et al., 2016) . Pupillometry is a non-invasive and cost-effective method to determine autonomic nerve activity (Granholm and Steinhauer, 2004) . The majority of studies analysing the effect of drugs on the pupil diameter were performed with opioids finding that they cause pupil constriction (miosis) (Harris et al., 2017; LevyCooperman et al., 2016; Mangas-Sanjuan et al., 2016; Pickworth et al., 1990) . Furthermore, it was shown that carriers of CYP2D6 EM and PM phenotypes treated with tramadol experienced a decrease of response amplitude, constriction velocity and reaction duration as well as an increase of latency of the pupil (Fliegert et al., 2005) , however, the effect was minor in subjects carrying PM phenotype.
In a previous study, the refraction and eye anterior segment parameters were investigated in schizophrenic patients under antipsychotic treatment including ARI and healthy controls. Overall, no difference was found in their pupil diameter (Cumurcu et al., 2015) . However, in another study it was confirmed that olanzapine causes a decrease in pupil/iris ratio compared to placebo (Kleinloog et al., 2012) . Therefore, only two studies were performed to analyse antipsychotic effects on the pupil and only one included ARI. This drug could affect the pupil size due to its partial agonist activity at dopamine D2, D3 and 5-HT1A receptors, and antagonist activity at 5-HT2A and 5-HT7 receptors (de Bartolomeis et al., 2015; Lawler et al., 1999; Stip and Tourjman, 2010) , as it was proved that serotonin and dopamine are effectors on various types of muscles including the sphincter pupillae and the dilator pupillae (Costagliola et al., 2008) . Consequently, ARI administration and the presence of polymorphisms in the genes coding for the receptors involved in its mechanism of action may affect the response of the pupil.
The aim of the current study was to evaluate if ARI affects various pupillometric parameters in healthy subjects. Furthermore, the connection to pharmacokinetics and pharmacogenetics was also discussed.
Materials and methods

Study population
A single-dose bioequivalence trial was performed at the Clinical Trial Unit of Hospital de la Princesa (Madrid, Spain) including 36 healthy volunteers (18 men and 18 women) who received 10 mg ARI orodispersible tablets. The protocol was approved by the Research Ethics Committee duly authorised by the Spanish Drugs Agency and under the guidelines of good clinical practice. All subjects were adequately informed about the study and, if agreeing to participate, signed an informed consent form before inclusion.
Subjects were included if they met all the inclusion criteria: male and female volunteers, aged between 18-55 years, free from any known organic or psychiatric conditions, normal vital signs and electrocardiogram (ECG), normal medical records and physical examination which were relevant to this trial, and no clinically significant abnormalities in haematology, biochemistry, serology and urine tests. Tests monitoring pregnancy and illicit drug use were performed on urine samples and repeated each hospitalisation day before drug administration. Subjects were excluded if they met any of the following criteria: received prescribed pharmacological treatment in the last 15 days or any kind of medication in the last 48 h prior to receiving the study medication, body mass index (BMI) outside the 18.5-30.0 kg/m 2 range, history of drug allergy, suspected consumers of controlled substances, smokers, daily alcohol consumers and/or acute alcohol poisoning in the previous week, having donated blood in the last month, pregnant or breastfeeding women as well as investigational drug study participants in the previous three months. Subjects were free to withdraw from the study at any time.
Study design and procedures
The clinical trial was a phase 1, single oral dose, randomised, crossover, two periods, two sequences, open-label, single-centre study with blind determination of the plasma concentrations of ARI and DARI. The volunteers received 10 mg orodispersible ARI tablets. The drug was administered to each healthy volunteer at the same time in each period. Every day the first volunteer received the drug at 09:00 and the last one at 09:25. In the first period, each volunteer received a single dose of one formulation of ARI (test or reference). In the second period, after a washout time frame of 28 days, each volunteer received the same dose of the other formulation. Volunteers fasted from 10 h before until five hours after drug administration. Before drug administration, volunteers rinsed their mouth with 20 mL of water. The reference formulation was Abilify (Otsuka Pharmaceutical Laboratories Europe, London, UK).
Twenty blood samples were collected from baseline (before administration) until 72 h after dosing. Samples were centrifuged at 3500 rpm (1900 G) for 10 min and then the plasma was collected and stored at −20°C until the determination of plasma concentrations by the analytical laboratory.
Plasma concentrations of ARI and DARI
Plasma concentrations of ARI and DARI were measured by high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) method validated in our laboratory (Wojnicz et al., 2017) , with a lower limit of quantification of 0.18 ng/mL for ARI and 0.35 ng/mL for DARI. Stable isotope labelled ARI (ARI-D8) was used as an internal standard for both analytes. For analyte extraction we used three-step microelution-solid-phase extraction (Oasis PRiME HLB 96-well μElution Plate) from 200 μL of human plasma. An octadecyl carbon chain (C18)-bonded silica, reversed phase HPLC column with pentafluorophenyl ligand (to ensure extra selectivity), was used for chromatographic separation. A combination of ammonium formate in Milli-Q water (5 mM; pH 4.0) and acetonitrile (65:35, v/v) was used as the mobile phase at a flow rate of 0.6 mL/min. The total chromatographic run time was eight minutes, constituting of a five-minute run time and a threeminute re-equilibration time. Overall, a volume of 5 μL eluent was injected into the HPLC-MS/MS system. Linearity was confirmed for concentration ranges from 0.18-110 ng/mL for ARI and 0.35-100 ng/mL for DARI.
Pharmacokinetic assessments
Pharmacokinetic parameters were calculated by non-compartmental analysis using WinNonlin Professional (Version 2.0, Pharsight Corporation, Palo Alto, California). The maximum plasma concentration (C max ) and the elapsed time to reach the maximum plasma concentration (T max ) were obtained directly from raw data. The total area under the curve (AUC) from administration to infinity (AUC 0− ∞) was calculated as the sum of AUC 0−t and the residual area (C t divided by k e , with C t as the last measured concentration and k e as the apparent terminal elimination rate, which was estimated by log-linear regression from the terminal portion of the log-transformed concentration-time plots). Half-life was calculated by dividing 0.693 by k e . The total drug clearance adjusted for bioavailability (Cl/F) was calculated by dividing the dose by the AUC 0− ∞ and adjusting for weight. Volume of distribution adjusted for bioavailability (Vd/F) was calculated as Cl/F divided by k e . The AUC and C max were adjusted for dose and weight (AUC/dW and C max /dW) and logarithmically transformed for statistical analysis.
For DARI, only AUC 0−t (truncated to 72 h), C max and T max were determined, because it was not possible to calculate the remaining parameters.
Pupillary light reflex (PLR) measurements
Pupillometric measurements were performed before drug administration and 2, 4, 6, 8, 10 and 12 h after drug administration recorded with a PRL 200 automated monocular infrared pupillometer (NeurOptics, Irvine, California, United States). Each measurement was performed in a hospital room with artificial illumination. Before starting the measurement, the subject was instructed to focus on a small target object -a wall chart -that was at least three meters away with the eye that was not being tested open (left eye). Stimuli were single light pulses with a fixed intensity of 180 µW (microwatts) during 154 ms. Visual light stimuli were generated using white light emitting diodes (LEDs) monocularly. The LED lightning source was placed approximately two centimetres away from the right eye and its largeness was 5×5 mm. Once the device was focused on the target pupil (right eye), a white light stimulus was flashed. The measurements were sampled at a frequency of 32 frames per second and lasted up to five seconds, allowing a full or partial recovery of the pupil size after light constriction. The above conditions were identical for all subjects to keep the measurements comparable. Additionally, it was of importance that the eye cup of the pupillometer was correctly fitted as it helps to reduce the possibility of stray light entering the eye during measurements. In order to adjust for the potential differences in luminosity, consequently in maximum pupil diameter, a digital light (lux) meter (PCE Iberica, S.L., Albacete, Spain) was used to measure the light intensity in lux immediately before each analysis. Light intensity was 96.08±76.89 lux (lm/m 2 ).
We monitored eight different pupillometric parameters as described in the user guide (NeurOptics, Inc., 2010). Maximum pupil diameter (MAX) and minimum pupil diameter (MIN) represent the pupil diameter before the constriction and just at the peak of the constriction, respectively. CON is the percentage of the constriction calculated by (MAX-MIN)/MAX. LAT is the latency and it represents the time of the onset of the constriction. ACV and MCV are the average and the maximum constriction velocity, respectively. The negative sign is to differentiate constriction from dilation, which is the opposite movement. ADV is the average dilation velocity and represents the average pupillary velocity, when, after reaching its constriction, the pupil tends to recover and dilates back to its initial resting size. T75 is the total time taken by the pupil to recover 75% of the initial resting pupil size after it reached the peak of constriction.
Genotyping
DNA was extracted from 1 mL peripheral blood samples using a MagNA Pure LC DNA Isolation Kit in an automatic DNA extractor (MagNa Pure System, Roche Applied Science, Indianapolis, Indiana, USA) and quantified spectrophotometrically in a NanoDrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, Delaware, USA).
The CYP2D6 *3, *4 and *5 polymorphisms were analysed by reverse transcription polymerase chain reaction (RT-PCR) using LightCyler 2.0 instrument (RocheDiagnostics, Mannheim, Germany). The primers and the probes were designed by TIB MOLBIOL (Berlin, Germany) for this purpose.
ABCB1 C3435T, C1236T, G2677T/A, DRD2 rs6277, rs1800497, DRD3 rs6280, CYP2D6 *6, *7 and *9, HTR2A rs6313, rs6314 and HTR2C rs3813929 polymorphisms were genotyped using a StepOnePlus PCR instrument (Applied Biosystems, Foster City, California, USA). To determine the copy number variations (CNVs) in the CYP2D6 gene a TaqMan Copy Number Assay (Applied Biosystems, Foster City, California) was used, which detects a specific sequence on exon 9. For statistical reasons, all the samples were run in quadruplicates in the instrument. A positive control was used from Coriell Institute with a known copy number of CYP2D6 (three copies, Coriell ID: NA17221). The assay was performed with an endogenous control, TaqManRNase P Copy Number Reference Assay (Applied Biosystems, Foster City, California, USA). To determine the exact number of CYP2D6 copies we used CopyCaller Software (Applied Biosystems, Foster City, California, USA) that uses the comparative ΔΔCT method (Schmittgen and Livak, 2008) .
Statistical analysis
Statistical analysis was performed with the SPSS 19.0 software (SPSS Inc., Chicago, Illinois, USA). Values of p lower or equal than 0.05 were considered significant. The Hardy-Weinberg equilibrium was estimated for all analysed variants. Deviations from the equilibrium were detected by comparing the observed and expected frequencies using a Fisher exact test based on the De Finetti program (available at http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
The changes between the recorded values in different time points in pupillometric parameters (MAX, MIN, T75, MCV, CON, ACV, ADV, LAT) after the administration of ARI were analysed by repeated measures analysis of variance (ANOVA). The values were adjusted for differences in light intensity immediately before each analysis. Differences in pharmacokinetic and pupillometric parameters between individuals with distinct genotypes were statistically analysed by a parametric univariate analysis (t-test or ANOVA). A simple linear regression was performed to predict pupillometric parameters based on pharmacokinetic data (AUC, C max , T 1/2 , T max ). Multiple linear regression models were used to study factors related to all the pupillometric and pharmacokinetic dependent variables. Models for each dependent with standardised (β) regression coefficients are shown in results. CYP2D6 genotypes were classified in four phenotypes (PM, intermediate metaboliser (IM), extensive (normal) metaboliser (EM) and UM) according to the method used by Gaedigk et al., which is based on the functionality of alleles (Gaedigk et al., 2008) , but PM and UM were not found in this study.
Results
Demographic and genotypic characteristics
Thirty-six healthy volunteers were included in the bioequivalence study. All of them completed it, however, only 32 (17 men and 15 women) participated in the pharmacogenetic and the pupillometric analyses. Average age was distinctively different between men and women, but it did not reach the significant level (25.6±7.0 years and 31.0±10.7 years, respectively, p=0.06).
Notably, men had greater weight than women (77.4±8.7 kg and 62.4±8.8 kg, respectively, p<0.001), but the BMI values did not differ significantly (25.5±2.2 kg/m 2 and 23.8±3.5 kg/m 2 , respectively, p=0.06). All the subjects were Caucasian.
The genotype frequencies of the analysed genes are shown in Table 1 . All genetic variants were in Hardy-Weinberg equilibrium (p⩾0.05). Differences in genotype frequencies were found between men and women in CYP2D6 phenotype and DRD2 rs6277 and HTR2C rs3813929 polymorphisms, as shown in Table 1 . In the case of HTR2C rs3813929 polymorphism, it is explained by the location of the gene on chromosome X.
Pharmacokinetic analysis
Mean and standard deviation (SD) of ARI and DARI pharmacokinetic parameters are shown in Table 2 . After adjusting for weight, sex differences were found in ARI Vd/F (p=0.01) and in Cl/F (p=0.01) as women had higher and lower levels than men, respectively. Women showed higher T 1/2 , C max and AUC 0-t (p<0.05), but these differences disappeared after adjusting for weight. No differences were found between the sexes in DARI pharmacokinetics.
The effect of ARI on pupillometry and its relationship with pharmacokinetics
Following oral administration of ARI, a significant decrease was observed at two hours in pupillary parameters MAX, MIN, T75 and MCV, therefore, the pupil showed constriction. The changes reached their peak value at 2-4 h after drug administration, concurrently when ARI reached the maximum concentration of 48 ng/mL (C max ) at 2.9 h (T max ). Thereafter, they started to increase linearly in time until the last measurement point (12 h) (Figure 1 ). No differences were found between men and women in any of these pupillometric parameters.
Mean and SD of baseline, two hours after drug administration and maximum values of the pupillometric parameters are shown in Table 3 .
Moreover, C max and T 1/2 had an influence on MAX and MIN pupillometric parameters. When MAX was estimated, it was found that it has an indirect relationship with T 1/2 (non-standardised β coefficient=−0.01, p=0.02, r 2 =0.16, Cohen's f 2 =0.19). However, no significant effect was found with C max (non-standardised β coefficient=−0.04, p=0.09, r 2 =0.10, Cohen's f 2 =0.11). Regarding MIN, we detected the same tendency: an indirect relationship with T 1/2 , (non-standardised β coefficient=−0.01, p=0.01, r 2 =0.18, Cohen's f 2 =0.22), however, C max did not reach the statistically significant level (non-standardised β coefficient=−0.01, p=0.10, r 2 =0.02, Cohen's f 2 =0.01). No interrelation was found with the remaining parameters. Moreover, after analysing heart rate variability as another marker of autonomic function, no association was found with the pupillometric parameters at different time points.
The influence of polymorphisms on pupillometry
TT subjects for the rs6313 single nucleotide polymoprhism (SNP) in HTR2A gene showed higher MCV (p=0.001, r 2 =0.399, Cohen's f 2 =0.664) and MAX (p=0.030, r 2 =0.226, Cohen's f 2 =0.292) (Figure 2) . Furthermore, carriers of T allele for the rs3813929 of HTR2C showed higher T75 (p=0.044, r 2 =0.131, Cohen's f 2 =0.151), but this effect disappeared after Bonferroni correction (p=0.078). Additionally, the multivariate analysis revealed that TT subjects for this SNP show higher MAX (p=0.008, r 2 =0.214, Cohen's f 2 =0.272) and MCV (p=0.000, r 2 =0.348, Cohen's f 2 =0.534) values. Besides, carriers of Gly/Gly genotype for DRD3 rs6280 SNP showed significantly lower MCV values (p=0.013, r 2 =0.474, Cohen's f 2 =0.901). Additionally, AG heterozygotes for DRD2 rs6277 SNP showed higher T75 values (p=0.047, r 2 =0.125, Cohen's f 2 =0.143).
However, polymorphisms in ABCB1 (C3435T, C1236T, G2677T/A) and DRD2 (rs1800497) genes and CYP2D6 phenotypes had no influence on pupillometric parameters.
Pharmacokinetics and polymorphisms
Bivariate and multivariate analyses revealed associations between several pharmacokinetic parameters and polymorphisms in the analysed genes. CYP2D6 IMs showed higher AUC (p=0.010, r 2 =0.198, ACV: average constriction velocity; ADV: dilation velocity; CON: percentage of the constriction; LAT: latency; MAX: maximum pupil diameter; MCV: maximum constriction velocity; MIN: minimum pupil diameter; T75: total time taken by the pupil to recover 75% of the initial resting pupil size after it reached the peak of constriction. a p⩽0.001 related to the baseline value; b p⩽0.05 related to the baseline value.
Discussion
Sex influence on pharmacokinetics ARI pharmacokinetics is affected by sex based on a previous study performed by our group as AUC, C max , T 1/2 and Vd/F were higher in women than in men (Belmonte et al., 2016) . In the current analysis, these results were verified and additionally Cl/F was lower in women than in men. These findings are consistent with previous studies (Islam et al., 2017; Schwartz, 2003) . However, they are mostly explained by differences in bodyweight as it is shown in the drug label. It states that C max and AUC of ARI are 30-40% higher in women than in men (Abilify, Otsuka Pharmaceutical, Co., Ltd., 2014) . Sex-related variability in pharmacokinetics of psychotropic drugs can be due to the differences in gastric acidity, intestinal motility, bodyweight and Figure 2 . Association of 5-hydroxytryptamine receptor 2A (HTR2A) rs6313 genotypes with MCV and MAX pupillometric parameters, 5-hydroxytryptamine receptor 2A (HTR2C) rs3813929 genotypes with maximum constriction velocity (MCV) and maximum pupil diameter (MAX), dopamine D2 receptor (DRD2) rs6277 genotypes with T75 and dopamine D3 receptor (DRD3) rs6280 genotypes with MCV. T75: total time taken by the pupil to recover 75% of the initial resting pupil size after it reached the peak of constriction.
*p⩽0.05; **p⩽0.001, · shows the outliers.
composition, blood volume, liver enzymes (mainly the cytochrome P450), renal excretion or the sensitivity to side effects and toxicity of drugs (Marazziti et al., 2013) .
Pharmacokinetics and pupillometry
Pupillary dilation as a marker of drug occupancy and action has been measured several times in previous studies (Graur and Siegle, 2013; Siepmann et al., 2007) . However, mostly the effects of opioid drugs were analysed. Miosis is thought to be caused by a direct opioid effect during the use of these drugs on μ receptors in the autonomic nucleus of the oculomotor nerve (Larson et al., 1997) . In addition to agonist activity at the µ-opioid receptor, tramadol, an opioid drug used during acute or chronic pain, also inhibits the re-uptake of the neurotransmitters norepinephrine and 5-HT in the descending inhibitory pain pathways, thus, facilitating 5-HT release (Raffa et al., 1992) . Based on this information, as ARI has antagonist activity at 5-HT2A and 5-HT7 receptors, we suspected that the drug has a similar effect on the pupil as tramadol has. According to our knowledge, the antipsychotic effect on pupillary motility was explored only in patients treated with olanzapine, where it caused a decrease in pupil/iris ratio (Kleinloog et al., 2012) . In another study, antipsychotic drugs (risperidone, olanzapine, ARI, amilsulpiride, clozapine, quetiapine and ziprasidone) did not cause a change in pupil diameter compared with placebo (Cumurcu et al., 2015) .
The pupillary parameters MAX, MIN, MCV and T75 significantly changed after 2-4 h of drug administration, exactly when ARI reached C max . The background of these changes could be rooted in the fact that 5-HT is an effector on various types of smooth muscles, functioning also at the level of ciliary muscle and sphincter of the pupil (Costagliola et al., 2008) . 5-HT and its receptors 5-HT1A and 5-HT2A are proven to be abundantly expressed in mammalian iris-ciliary body complex (ICB) (Barnett and Osborne, 1993a; Tobin and Osborne, 1989; Tobin et al., 1988) . Additionally, it is known that higher levels of 5-HT causes pupil dilation when it binds to its receptors (Yu et al., 2004) . Moreover, dopamine can cause pupil dilation or constriction through sympathetic and parasympathetic nerves, respectively (Spiers and Calne, 1969) . Based on our results, pupil constriction could be due to the partial antagonist activity of ARI at 5-HT2A and 5-HT7 receptors, because ARI is a partial agonist at dopamine receptors, therefore, it would cause dilated pupils. Therefore, clinicians could assess autonomic nervous system activity in schizophrenic patients treated with antipsychotic drugs. This would allow to estimate subclinical signs with a noninvasive method like pupillometry.
Polymorphisms and pupillometry
So far only a few related studies have been carried out to analyse the relationship between pupil miosis and mydriasis in response to drugs and genetic polymorphisms. When evaluating the effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol, the mean maximal decrease speed in pupil diameter was 1.5-fold longer in UMs compared with EMs (Fliegert et al., 2005) . In contrast, in our study, no association was found between CYP2D6 phenotypes when analysing ARI pharmacokinetics and the pupillometric parameters. Therefore, the effect of CYP2D6 on the pupil was not measurable. Additionally, probably due to the low sample size, we could not find UMs and PMs among the studied group.
No ABCB1 genetic variants were found which could predict pupil miotic and mydriatic effects while administrating the opioid drug loperamide (Skarke et al., 2003) . To the extent of our knowledge, no other study was carried out to analyse the genetic differences in ABCB1 related to pupil contraction. We could not associate C3435T, C1236T and G2677T/A polymorphisms in the gene with any of the pupillometric parameters. Second-generation antipsychotics such as amisulpride, ARI, risperidone and paliperidone are transported by P-gp (Moons et al., 2011) . A P-glycoprotein (P-gp) inhibitor, HM30181, increases the oral bioavailability of co-administered drugs (Kim et al., 2014, p. 30; Kwak et al., 2010) . Pupil diameter was slightly decreased or remained almost the same over time when loperamide was administered alone or co-administered with HM30181, respectively, whereas it was markedly decreased when quinidine -a CYP2D6 inhibitor -was co-administered, suggesting that the influence of P-gp could be minor compared to CYP2D6 (Kim et al., 2014, p. 30; Skarke et al., 2003) .
It is known that dopamine administration produces marked dilatation of the pupil (Ong and Bruning, 1981; Spiers and Calne, 1969) . The administration of neurotensin, which is a neuromodulator of dopamine transmission, induced miosis in the rabbit eye (Hernandez and Jennes, 1990) . We found that heterozygotes for DRD2 rs6277 SNP showed higher T75 values and Gly/Gly homozygotes for DRD3 rs6280 SNP showed lower MCV values. ARI is a partial agonist for dopamine D2 and D3 receptors (Burris et al., 2002) . Based on our previous results, we concluded that ARI effects on the pupil are conceivably due to its antagonism at 5-HT receptors. However, as we found a relationship between dopamine receptor genes and MCV and T75 values, presumably the mechanism is more complex and further studies are needed to confirm our findings.
We found that TT subjects of HTR2A rs6313 polymorphism showed higher MCV and MAX values and carriers of T allele of HTR2C rs3813929 showed higher T75 value. 5-HT receptors, in particular the 5-HTlA subtype, may be associated with the iris sphincter muscle and suggest their involvement in the regulation of pupil size (Barnett and Osborne, 1993b) . This notion was further strengthened by the finding that pupil size is decreased by the intravenous injection of ketanserin, which is an antagonist primarily of 5-HT2 receptors (Krootila et al., 1987) . ARI has agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors, therefore, the polymorphisms in these genes may have a role in showing distinct pupil phenotypes in response to the drug.
Pharmacokinetics and polymorphisms
Our study confirms the impact of CYP2D6 phenotypes on ARI pharmacokinetics (Hendset et al., 2007; Suzuki et al., 2014) . In our previous study, the AUC 0-t of ARI was increased by 20% in IMs and by 50% in PMs compared to EMs (Belmonte et al., 2018) . In the current analysis, we obtained matching results as CYP2D6 IMs showed a higher AUC (32%), C max (26%) and T 1/2 (42%) values than EMs. Based on these results, a dose reduction could be recommended for IMs, but the US Food and Drug Administration (FDA) only recommends it for PMs, a phenotype which we did not find among our subjects (Abilify, Otsuka Pharmaceutical, Co., Ltd., 2014) .
To date, there are no consistent findings about the role of polymorphisms in ABCB1. In our previous study, we showed that C1236T SNP has an influence on the pharmacokinetics of ARI, which could be caused by the lower P-gp activity of T/T subjects (Belmonte et al., 2018) . In a study performed in paediatric patients, an effect of both polymorphisms was revealed on ARI pharmacokinetics as subjects with the 2677TT and 3435TT genotypes had lower ARI concentrations (Rafaniello et al., 2017) . On the contrary, we found that T allele carriers of C3435T polymorphism showed greater AUC values. To date, there are no consistent results about the role of ABCB1 polymorphisms; therefore, further studies should be performed before dose adjustments.
Study limitations
The main limitation of our study is the low sample size, as only 32 healthy subjects were included. Therefore, it is important to interpret these results with caution. This could be the reason why we could not find PM and UM phenotypes for CYP2D6. Studies including more subjects are necessary to increase the statistical reliability of the results. Moreover, we administered a single dose of ARI, which prevented us from assessing longer-term effects on the pupil. Furthermore, pharmacokinetic and pharmacogenetic effects on pupillometry could be different in psychotic patients receiving long-term treatment compared to healthy volunteers. Therefore, we are not able to apply pupillometry as a tool to assess autonomic dysfunction in a clinical setting yet, further studies are needed.
Conclusion
ARI administration produced pupil constriction: MAX, MIN, MCV and T75 parameters were decreased to the peak value when ARI reached C max . Additionally, the effects of ARI on pupillometric parameters are associated with polymorphisms in 5-HT (HTR2A and HTR2C) and dopamine (DRD2 and DRD3) receptor genes. The pharmacokinetics of ARI is affected by sex as Vd/F was higher, and Cl/F was lower in women than in men. Moreover, CYP2D6 phenotypes had an impact on AUC, C max and T 1/2 of ARI. Additionally, ABCB1 polymorphisms were associated with T 1/2 and AUC values. In conclusion, pupillometry could be an important and useful tool to assess autonomic nervous system activity during antipsychotic drug treatment. It could be used to estimate the subclinical signs of adverse effects, therefore predicting them beforehand. Furthermore, the main advantage of such measurements is their non-invasive character.
Silverpharma, Teva and Zambon. The remaining authors declare no conflicts of interest.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: D Koller is cofinanced by the H2020 Marie Sklodowska-Curie Innovative Training Network 721236 grant. M Saiz-Rodríguez and P Zubiaur are co-financed by Consejería de Educación, Juventud y Deporte from Comunidad de Madrid and Fondo Social Europeo.
